rejuvant life tabs

The trillion dollar upside to longevity

Latest articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...
Rejuvant

New economic model estimates that targeting aging has larger economic gains than eradicating individual diseases: time for a policy pivot?

Although life expectancy has increased over the last few years, there is an increment in the number of years spent in poor health [1]. Treatments targeting aging can lead to both healthier and longer lives. Therefore, there is a great emphasis on ‘healthy aging’ and a growing body of research focusing on its biological aspects [2].

Longevity.Technology: In a recent study, Andrew J Scott (London Business School), David Sinclair (Harvard Medical School) and Martin Ellison (University of Oxford) [3] evaluated the value of extending life expectancy, compressing morbidity and targeting aging. They took an economic perspective by using the value of statistical life (VSL) model, calibrated to current US economic, health, and demographic data.

Andrew J Scott (London Business School), David Sinclair (Harvard Medical School), Martin Ellison (University of Oxford)
L-R: Andrew J Scott (London Business School), David Sinclair (Harvard Medical School), Martin Ellison (University of Oxford)

This model allowed the researchers to place a monetary value on the financial gain from longer life, better health and changes in the rate at which we age [4,5]. VSL represents the sum of the value of each remaining year of life, discounted to the present day and weighted by the survival rate.

The study revealed that a compression of morbidity that improves health is more valuable than further increases in life expectancy. However, in order to raise economic gains, longevity has to improve too. Slowing down aging reduces the rate at which biological damage occurs and improves both health and mortality.

longevity $367tn

The authors calculated a slowdown in aging that increases life expectancy by one year is worth $38 trillion, and for ten years $367 trillion!

Elevant

longevity explainer

How much can aging be realistically slowed? Is it more valuable to slow down aging or reduce specific diseases? A previous study [6] evaluated the impact of metformin – a drug used in the treatment of type 2 diabetes and that was found to protect against several age-related diseases [7] – on the incidence of various age-related comorbidities in diabetic men.

The results revealed a substantial reduction in the incidence of key age-related diseases, including dementia, cardiovascular disease, cancer and depression after five years of treatment. Due to the rising prevalence of age-related comorbidities, treatments targeting aging are valuable, as their impact will be felt across multiple diseases [8]. The study revealed that targeting aging has potentially larger economic gains than eradicating individual diseases.


 

… the US population is expected to see an increase in its average age of 4.0 years by 2050 and a decline of 1.6 million people … This effect is worth $256.7 billion for +1 year life …

 


 

Improvements in aging increase the average age of society, improve the quality of life in old age and increase the number of older people. Ellison, Scott and Sinclair [3] estimate that the US population is expected to see an increase in its average age of 4.0 years by 2050 and a decline of 1.6 million people. The data suggest that more people will be alive at older ages and in better health in 2050. This effect is worth $256.7 billion for +1 year life expectancy and $8.8 trillion for +10 years life expectancy. Investing in treatments targeting aging would have a positive impact on longevity, ultimately leading to gains in health and economy.

[1] https://pubmed.ncbi.nlm.nih.gov/33069325/
[2] https://us.macmillan.com/books/9781250230867
[3] https://tinyurl.com/3p582rsa
[4] https://www.journals.uchicago.edu/doi/abs/10.1086/379932
[5] https://www.nber.org/papers/w11405
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654524/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943638/
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938188/

Image credit: mohamed_hassan / Pixabay

1 COMMENT

Comment on this article

Christos Evangelou
Since the completion of his undergraduate and doctoral studies in Molecular Biosciences, Christos has been working in the medical communications industry, driven by his passion for communicating sciences. Apart from helping researchers to publish their studies, Christos writes articles related to sciences and medicine.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Gerostate Alpha opens crowdfunded capital raise

Buck Institute-founded start-up Gerostate Alpha seeks to crowdfund its biotech platform. When Y Combinator so likes your ideas, it gives you $1 million to start...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

New research institute focuses on science of aging

New Bakar Aging Research Institute aims to drive deeply collaborative research to enhance translational medicine, progressing novel therapies from lab to clinic to community. UC...
Supps report ad middle